Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis

NCT06222034 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT06222034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06222034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis
Lead sponsor
Alfasigma S.p.A.
Phase
Phase 1
Overall status
Terminated
Start date
May 13, 2024
Completion date
June 17, 2026
Enrollment
9 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis